Health

Just 30 patients reduced their GLP-1 doses and mostly kept the weight off. The findings sound promising for cost savings, but the study's limitations tell a more complex story about what we can actually conclude.

The $449/month workplace offering expands Lilly's direct-distribution model beyond individual consumers. With Medicare coverage launching and oral pills pending FDA approval, the timing suggests broader ambitions.

Analysis reveals the full scope of CDC restructuring: all vaccine advisors fired, hepatitis B recommendations ended, flu shots removed from child schedules. The measles surge is one symptom of broader institutional breakdown.

Conference research suggests modest bone risks, but contradictory peer-reviewed studies and missing context tell a different story. Here's how to read between the alarming headlines.

A nationwide moratorium targets future market entrants but leaves over 6,000 currently enrolled suppliers—the primary source of documented fraud—untouched. The policy gap raises questions about whether the fix matches the problem.

A Trump appointee overrode career scientists and detailed safety memos to reject Moderna's flu vaccine, then flipped the decision after industry backlash. The episode reveals cracks in the regulatory firewall between politics and science.

His schizophrenia "cure" statement follows a playbook: take preliminary research, strip away scientist warnings, repackage as breakthrough. The pattern puts vulnerable patients at risk.

New research links menopause to brain changes but can't determine if hormone therapy helps or hurts. The problem: women prescribed HRT already had different symptoms and brain health before treatment started.